An increase of cytochrome C oxidase mediated disruption of gemcitabine incorporation into DNA in a resistant KB clone

Biochemical Pharmacology

Volumn 73, Issue 12, 2007, Pages 1927-1938

  Liu, Xiyong ^a   Zhou, Bingsen ^a   Mi, Shu ^a   Xue, Lijun ^a   Shih, Jennifer ^a   Lee, Janice ^a   Chau, Jennifer ^a   Un, Frank ^a   Yen, Yun ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

ATP; Cytochrome C oxidase; Drug resistance; Gemcitabine; Ribonucleotide reductase

Indexed keywords

ADENOSINE TRIPHOSPHATE; CYTOCHROME C OXIDASE; CYTOCHROME C OXIDASE 3; DNA; GEMCITABINE; HYDROXYUREA; MESSENGER RNA; PROTON TRANSPORTING ADENOSINE TRIPHOSPHATE SYNTHASE; SODIUM AZIDE; TRITIUM; UNCLASSIFIED DRUG;

ARTICLE; CELL CLONE; CONTROLLED STUDY; DNA MICROARRAY; DRUG METABOLISM; DRUG SENSITIVITY; DRUG TRANSPORT; ENZYME ACTIVITY; ENZYME SUBUNIT; GENE EXPRESSION PROFILING; GENE OVEREXPRESSION; GENE SEQUENCE; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SEQUENCE ANALYSIS; UPREGULATION;

ADENOSINE TRIPHOSPHATE; ANTIMETABOLITES, ANTINEOPLASTIC; BLOTTING, WESTERN; CLONE CELLS; DEOXYCYTIDINE; DNA; DRUG RESISTANCE, NEOPLASM; ELECTRON TRANSPORT COMPLEX IV; ENZYME INHIBITORS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KB CELLS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; POLYMERASE CHAIN REACTION; RNA, MESSENGER; SODIUM AZIDE;

EID: 34247567115     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2007.03.014     Document Type: Article

References (44)

1. Galmarini C.M., Mackey J.R., and Dumontet C. Nucleoside analogues and nucleobases in cancer treatment. Lancet Oncol 3 (2002) 415-424
2. Heinemann V., Schulz L., Issels R.D., and Plunkett W. Gemcitabine: a modulator of intracellular nucleotide and deoxynucleotide metabolism. Semin Oncol 22 (1995) 11-18
3. Plunkett W., Huang P., Xu Y.Z., Heinemann V., Grunewald R., and Gandhi V. Gemcitabine: metabolism, mechanisms of action, and self-potentiation. Semin Oncol 22 (1995) 3-10
4. Huang P., Chubb S., Hertel L.W., Grindey G.B., and Plunkett W. Action of 2′,2′-difluorodeoxycytidine on DNA synthesis. Cancer Res 51 (1991) 6110-6117
5. Gandhi V., Legha J., Chen F., Hertel L.W., and Plunkett W. Excision of 2′,2′-difluorodeoxycytidine (gemcitabine) monophosphate residues from DNA. Cancer Res 56 (1996) 4453-4459
6. Galmarini C.M., Mackey J.R., and Dumontet C. Nucleoside analogues: mechanisms of drug resistance and reversal strategies. Leukemia 15 (2001) 875-890
7. Mackey J.R., Jennings L.L., Clarke M.L., Santos C.L., Dabbagh L., Vsianska M., et al. Immunohistochemical variation of human equilibrative nucleoside transporter 1 protein in primary breast cancers. Clin Cancer Res 8 (2002) 110-116
8. Achiwa H., Oguri T., Sato S., Maeda H., Niimi T., and Ueda R. Determinants of sensitivity and resistance to gemcitabine: the roles of human equilibrative nucleoside transporter 1 and deoxycytidine kinase in non-small cell lung cancer. Cancer Sci 95 (2004) 753-757
9. Garcia-Manteiga J., Molina-Arcas M., Casado F.J., Mazo A., and Pastor-Anglada M. Nucleoside transporter profiles in human pancreatic cancer cells: role of hCNT1 in 2′,2′-difluorodeoxycytidine-induced cytotoxicity. Clin Cancer Res 9 (2003) 5000-5008
10. Mackey J.R., Mani R.S., Selner M., Mowles D., Young J.D., Belt J.A., et al. Functional nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell lines. Cancer Res 58 (1998) 4349-4357
11. Galmarini C.M., Jordheim L., and Dumontet C. Role of IMP-selective 5′-nucleotidase (cN-II) in hematological malignancies. Leuk Lymphoma 44 (2003) 1105-1111
12. Galmarini C.M., Clarke M.L., Jordheim L., Santos C.L., Cros E., Mackey J.R., et al. Resistance to gemcitabine in a human follicular lymphoma cell line is due to partial deletion of the deoxycytidine kinase gene. BMC Pharmacol 4 (2004) 8
13. Ruiz van Haperen V.W., Veerman G., Eriksson S., Boven E., Stegmann A.P., Hermsen M., et al. Development and molecular characterization of a 2′,2′-difluorodeoxycytidine-resistant variant of the human ovarian carcinoma cell line A2780. Cancer Res 54 (1994) 4138-4143
14. Davidson J.D., Ma L., Flagella M., Geeganage S., Gelbert L.M., and Slapak C.A. An increase in the expression of ribonucleotide reductase large subunit 1 is associated with gemcitabine resistance in non-small cell lung cancer cell lines. Cancer Res 64 (2004) 3761-3766
15. Goan Y.G., Zhou B., Hu E., Mi S., and Yen Y. Overexpression of ribonucleotide reductase as a mechanism of resistance to 2,2-difluorodeoxycytidine in the human KB cancer cell line. Cancer Res 59 (1999) 4204-4207
16. Richter O.M., and Ludwig B. Cytochrome c oxidase-structure, function, and physiology of a redox-driven molecular machine. Rev Physiol Biochem Pharmacol 147 (2003) 47-74
17. Ludwig B., Bender E., Arnold S., Huttemann M., Lee I., and Kadenbach B. Cytochrome C oxidase and the regulation of oxidative phosphorylation. Chembiochem 2 (2001) 392-403
18. Anderson S., Bankier A.T., Barrell B.G., de Bruijn M.H., Coulson A.R., Drouin J., et al. Sequence and organization of the human mitochondrial genome. Nature 290 (1981) 457-465
19. Capaldi R.A. Structure and function of cytochrome c oxidase. Annu Rev Biochem 59 (1990) 569-596
20. Shoji K., Tanigawa M., Hori K., Tomozawa Y., and Yamanaka T. The effects of several nucleotides on the molecular state and catalytic activity of Thiobacillus novellus cytochrome c oxidase. ATP affects the oxidase uniquely. Eur J Biochem 264 (1999) 960-964
21. Chen Y.R., Sturgeon B.E., Gunther M.R., and Mason R.P. Electron spin resonance investigation of the cyanyl and azidyl radical formation by cytochrome c oxidase. J Biol Chem 274 (1999) 24611-24616
22. Grandjean F., Bremaud L., Robert J., and Ratinaud M.H. Alterations in the expression of cytochrome c oxidase subunits in doxorubicin-resistant leukemia K562 cells. Biochem Pharmacol 63 (2002) 823-831
23. Denis-Gay M., Petit J.M., Mazat J.P., and Ratinaud M.H. Modifications of oxido-reductase activities in adriamycin-resistant leukaemia K562 cells. Biochem Pharmacol 56 (1998) 451-457
24. Liu X., Zhou B., Xue L., Qiu W., Shih J., Zheng S., et al. Nuclear factor Y regulation and promoter transactivation of human ribonucleotide reductase subunit M2 gene in a Gemcitabine resistant KB clone. Biochem Pharmacol 67 (2004) 1499-1511
25. Qiu W., Zhou B., Zou H., Liu X., Chu P.G., Lopez R., et al. Hypermethylation of growth arrest DNA damage-inducible gene 45 beta promoter in human hepatocellular carcinoma. Am J Pathol 165 (2004) 1689-1699
26. Leary S.C., Hill B.C., Lyons C.N., Carlson C.G., Michaud D., Kraft C.S., et al. Chronic treatment with azide in situ leads to an irreversible loss of cytochrome c oxidase activity via holoenzyme dissociation. J Biol Chem 277 (2002) 11321-11328
27. Karu T.I., Pyatibrat L.V., and Kalendo G.S. Photobiological modulation of cell attachment via cytochrome c oxidase. Photochem Photobiol Sci 3 (2004) 211-216
28. Zhou B., Mo X., Liu X., Qiu W., and Yen Y. Human ribonucleotide reductase M2 subunit gene amplification and transcriptional regulation in a homogeneous staining chromosome region responsible for the mechanism of drug resistance. Cytogenet Cell Genet 95 (2001) 34-42
29. Duxbury M.S., Ito H., Zinner M.J., Ashley S.W., and Whang E.E. RNA interference targeting the M2 subunit of ribonucleotide reductase enhances pancreatic adenocarcinoma chemosensitivity to gemcitabine. Oncogene 23 (2004) 1539-1548
30. Mansson E., Flordal E., Liliemark J., Spasokoukotskaja T., Elford H., Lagercrantz S., et al. Down-regulation of deoxycytidine kinase in human leukemic cell lines resistant to cladribine and clofarabine and increased ribonucleotide reductase activity contributes to fludarabine resistance. Biochem Pharmacol 65 (2003) 237-247
31. Zhou B., Mi S., Mo X., Shih J., Tsai J., Hu E., et al. Time and sequence dependence of hydroxyurea in combination with gemcitabine in human KB cells. Anticancer Res 22 (2002) 1369-1377
32. Harper M.E., Antoniou A., Villalobos-Menuey E., Russo A., Trauger R., Vendemelio M., et al. Characterization of a novel metabolic strategy used by drug-resistant tumor cells. Faseb J 16 (2002) 1550-1557
33. Pastor-Anglada M., Cano-Soldado P., Molina-Arcas M., Lostao M.P., Larrayoz I., Martinez-Picado J., et al. Cell entry and export of nucleoside analogues. Virus Res 107 (2005) 151-164
34. Belt J.A., Marina N.M., Phelps D.A., and Crawford C.R. Nucleoside transport in normal and neoplastic cells. Adv Enzyme Regul 33 (1993) 235-252
35. Griffith D.A., and Jarvis S.M. Nucleoside and nucleobase transport systems of mammalian cells. Biochim Biophys Acta 1286 (1996) 153-181
36. Hammond J.R., Lee S., and Ferguson P.J. [3H]gemcitabine uptake by nucleoside transporters in a human head and neck squamous carcinoma cell line. J Pharmacol Exp Ther 288 (1999) 1185-1191
37. Stein W.D. Kinetics of the multidrug transporter (P-glycoprotein) and its reversal. Physiol Rev 77 (1997) 545-590
38. Bergman A.M., Pinedo H.M., Veerman G., Kuiper C.M., and Peters G.J. Increased sensitivity to gemcitabine of P-gP and MRP overexpressing human non-small cell lung cancer cell lines. Adv Exp Med Biol 431 (1998) 591-594
39. Kashlan O.B., Scott C.P., Lear J.D., and Cooperman B.S. A comprehensive model for the allosteric regulation of mammalian ribonucleotide reductase. Functional consequences of ATP- and dATP-induced oligomerization of the large subunit. Biochemistry 41 (2002) 462-474
40. Scott C.P., Kashlan O.B., Lear J.D., and Cooperman B.S. A quantitative model for allosteric control of purine reduction by murine ribonucleotide reductase. Biochemistry 40 (2001) 1651-1661
41. Cooperman B.S., and Kashlan O.B. A comprehensive model for the allosteric regulation of Class Ia ribonucleotide reductases. Adv Enzyme Regul 43 (2003) 167-182
42. Qiu W., Zhou B., Darwish D., Shao J., and Yen Y. Characterization of enzymatic properties of human ribonucleotide reductase holoenzyme reconstituted in vitro from hRRM1, hRRM2, and p53R2 subunits. Biochem Biophys Res Commun 340 (2006) 428-434
43. Hsu C.H., Liou J.Y., Dutschman G.E., and Cheng Y.C. Phosphorylation of cytidine, deoxycytidine, and their analog monophosphates by human UMP/CMP kinase is differentially regulated by ATP and magnesium. Mol Pharmacol 67 (2005) 806-814
44. Zhou B.S., Ker R., Ho R., Yu J., Zhao Y.R., Shih J., et al. Determination of deoxyribonucleoside triphosphate pool sizes in ribonucleotide reductase cDNA transfected human KB cells. Biochem Pharmacol 55 (1998) 1657-1665